
usd pm et
summari rank one world largest pharmaceut compani offer wide rang
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
stock trade
revenu rose modest
improv declin
oncolog portfolio revenue
bellcow growth increas sale
year intern medicin vaccin
also solid perform
grow sale respect
often case larg drug compani
though strong growth newer drug
off-set larg extent loss exclus
loe declin sale older drug
sale eliqui anti-clot
xeljanz immunolog grow rapidli
like slightli
year overal sale best seller lyrica
neurosci like declin
precipit gener competit begin
june enbrel also continu
rapid declin due intens biosimilar
given mute sale growth near-term
expect ep declin around
long-term think earn growth
restor major new drug
robust pipelin contain phase
trial potenti biosimilar
next year expect tailwind
success newer drug mostli
off-set headwind gener biosmilar
competit older blockbust drug
accordingli modest ep growth
outlook still think enjoy advantag
mani smaller drugmak though due
larg drug portfolio diversifi across mani
therapeut area robust pipelin keep
fairli well-insul major swing
revenu up- downsid
expect larg dropoff lyrica enbrel
sale due gener biosimilar
competit strong growth exist
oncolog drug balanc
near-term though long-term see
even cancer drug come
pipelin sucess treat larg patient
popul breast lung prostat
target price ep estim
roughli line peer-averag
expect major next year
multipl late-stag pipelin result
forthcom could lead sale
growth risk view includ
potenti pipelin setback unexpect
risk assess reflect promin posit
global pharmaceut market afford
import competit oper financi
advantag divers portfolio drug
separ brand account annual
sale none contribut total
sale howev compani still subject risk
common pharmaceut compani
relat discoveri develop regulatori
clearanc success commerci new
drug well risk earlier-than-expect gener
competit success brand litig
may ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview one world largest biopharmaceut compani extens
oper drug develop manufactur market compani growth also augment
frequent acquisit largest market approxim sale
gener follow emer market europ
drug portfolio drug portfolio among divers global drug market view
compani top-sel drug prevnar famili vaccin billion sale
total lyrica billion sale total treatment nerv pain epilept seizur
key drug experienc robust growth includ ibranc billion sale
treat breast cancer grew sale eliqui billion stroke embol
grew xeljanz billion treatment arthriti ulcer coliti
grew sale
critic drug compani like consist success new drug growth
mode offset older drug declin sale due loss exclus competit new
improv treatment exampl type declin arthriti drug celebrex whose
sale peak around billion sinc fallen million patent
expir
next five year sever key patent expir occur hope off-set
growth newer drug patent expir includ lyrica sale
chantix/champix sale sutent sale ibranc sale
research develop effort continu off-set declin sale older drug
spend heavili research devlop keep new drug come pipelin
global drug market spend total billion billion
respect sale
march pipelin consist compound variou clinic trial phase
total phase final stage human clinic trial registr phase
fda approv final regulatori review drug market develop pipelin
includ potenti new treatment wide rang condit includ cancer obes arthriti heart
diseas diabet schizophrenia pain critic upcom pipelin event includ potenti fda approv
bavencio inlyta first-lin treatment renal cell carcinoma kidney cancer four potenti
biosimilar approv could repres billion opportun aggreg phase
readout rivipansel sickl cell diseas atop dermat addit phase
readout tanezumab osteoarthr chronic low back pain
market profil world-wide total prescript drug sale project grow compound annual
growth rate compound-annual-growth-rate period accord forecast evaluatepharma
key driver growth age develop popul especi babi
boomer age prime year health care need emerg market like see materi faster
growth prescript sale develop market howev due view
emerg market demand pharmaceut spur rise standard live global middl
class expand gain access advanc health care also develop market
govern increas health care spend
impact major develop june acquir billion
septemb acquir mediv mdvn billion curtail
acquisit activ total billion two-year period share repurchas
significantli increas billion billion
financi trend sale risen billion billion repres
three-year compound annual growth rate sale aid acquisit total
billion sinc start adjust pre-tax incom margin increas
primarili due reduct sg expens margin expens margin
adjust ep risen repres three-year compound-annual-growth-rate
improv profit margin help ep grow faster sale last three year also
note ep growth aid signific share buyback made net
repurchas billion worth share impact new stock issuanc reduc
share count process also paid billion dividend
cfo evp global
oper
pfizer global suppli
evp chief digit
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
neutral sinc march technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
outlook pharmaceut sub-industri
next year posit reflect
strong novel drug approv nda activ
food drug administr fda --
posit brand drug maker
repres lion share
improv gener profit margin
competit appear moder
overal posit view somewhat temper
expect lower growth overal
expect strong pace nda continu
next year aid continu robust
growth invest led major brand drug
compani banner year nda
fda new drug approv
repres surg approv compar
mani
new drug littl competit
provid tailwind brand drug
maker strong growth spend
primari driver novel approv uptick
industri increas
estim pace anoth year
growth septemb
growth mark rapid acceler
averag annual growth
side sub-industri
outlook earn growth gener
maker posit closer neutral fda
gener approv total
mani
compet version gener enter
sever gener
price deflat becam norm profit margin
contract surprisingli number
firm announc asset divestitur exit
 gener industri
bright side think lower competit
start impact note gener
approv tick vs
first materi declin least six
year also note move
averag gener applic lead
think anoth sign
mitig competit allow
moder gener deflat
modest improv gener profit margin
year ahead
anoth boost gener maker
record year fda first-gener approv
experienc
first-gener typic enter
market materi lower price
brand-nam counterpart allow
quick market share gain accordingli
major increas first-gener provid
revenu tailwind gener maker next
mitig posit outlook
sub-industri expect slower
prescript volum growth next
year strong gain health-insur
popul driven solid employ
growth view
think gain harder come
 approach full employ
remov tailwind prescript
volum growth assum
slower growth health plan roll gener
mean slower growth prescript volum
versu rise composit
drop
year date januari pharma
slip gain
base index
five-year market price perform
note sector sub-industri inform base
past perform indic futur perform
reli upon
compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
analyst research note compani news
pm et cfra keep hold opinion share pfizer inc
keep target peer-averag
ep estim ep vs beat consensu lower
ep estim initi sale
growth yoy similar rate seen first nine month
year led robust sale growth ibranc breast cancer sale
eliqui anti-clot sale xeljanz immunolog sale
three drug account sale
intern expans new indic expect three
continu robust growth year forecast overal sale fall
howev due lyrica neurosci sale like declin
precipit gener competit begin june view
long-term growth prospect favor howev due attract pipelin
promis phase trial on-going potenti three major
biosimilar approv /colin scarola
et cfra keep neutral outlook
sub-industri presid trump expect unveil plan
tackl high drug price today believ like focu two area
rebat pharmaci benefit manag pbm get drug firm discount
medicar get scenario believ trump push portion
rebat pbm receiv medicar discount pass patient
anticip trump propos allow medicar negoti drug price
drug firm ban law drug firm blame pbm
signific rise drug price increas rebat demand pbm
hand blame drug manufactur state need higher rebat
discount higher drug list price fda commission gottlieb
indic may examin rebat pbm receiv potenti kickback
potenti medicar negoti tabl expect share drug
firm react favor potenti downward pressur pbm /jeffrey loo
rais target ep estim
line peer-averag ep vs beat consensu
maintain ep estim deliv sale growth
yoy led strong growth sever blockbust drug includ
prevnar ibranc eliqui off-set greater
competit elsewher portfolio expect similar slow growth
scenario due expect loss exclus lyrica
sale despit weak sale growth adjust pre-tax incom yoy due
materi improv margin cog yoy
produc save fund valuabl yoy increas
support higher margin think critic
improv growth new approv indic oncolog sale
area show materi promis view new treatment breast
lung cancer approv /colin scarola
keep target ep estim
brand peer gener peer ep vs
ahead view partli lower tax rate vs year ago
howev sale growth sale growth forecast due
softer-than-expect sale arthriti drug xeljanz breast cancer drug
ibranc biosimilar competit europ enbrel along continu soft
sale essenti health unit lower gener price sale prevnar
fell sale intern sale say
compound develop could reach commerci
potenti achiev annual sale separ state
receiv fair valu sale consum health care
busi like retain invest unit howev also left
open potenti spin-off pursu joint ventur unit
keep target forward ep
estim brand peer gener peer ep
vs ahead view rais ep estim
aid lower share count repurchas share
lower tax rate juli
remain buy-back program sale fx benefit rose
innov essenti declin sale driven
solid sale growth eliqui ibranc xeljanz
partial off-set declin legaci product howev encourag
increas spend primarili relat advanc
late-stag develop program believ pipelin could produc
blockbust drug view aggress yet note
impact loss exclus product portfolio slow
significantli /jeffrey loo cfa
et cfra keep hold opinion share inc
announc reorgan three busi innov
medicin establish medicin consum health care effect
believ innov medicin account sale think
structur increas possibl spin establish
medicin unit see solid growth innov medicin modest
growth establish medicin consist off-pat drug
activ seek buyer consum health care unit past
year receiv appropri offer separ state
postpon drug price increas effect juli follow public
critic includ comment presid trump ceo spoke
presid trump state deferr give presid opportun
work drug price blueprint price return pre-juli
level end year presid blueprint come
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
